Pre-Market News Tracker — Wednesday, 22 July 2026

Thought of the day — “If you don't find a way to make money while you sleep, you will work until you die.” — Warren Buffett

Global market setup

Indian equity markets open today after a second straight lower close on Tuesday, when the Sensex slipped 238 points to 77,470.11 and the Nifty 50 eased about 51 points to 24,187.70, held back by elevated crude, continued foreign selling and weakness in HDFC Bank, even as market breadth stayed balanced with 2,087 shares advancing against 1,942 declining. The setup this morning is two-sided. Overnight, Wall Street rallied - the Dow rose 0.74% to 52,224.64, the S&P 500 added 0.89% to 7,509.20 and the Nasdaq gained 1.29% to 25,837.21, all three breaking three-day losing streaks as semiconductor stocks rebounded on strong Taiwan and South Korea export data. Against that, Brent crude held near USD 91 a barrel on US-Iran tensions, keeping the rupee near Rs. 96.36. The domestic newsflow is heavy: the United States has granted a two-year zero-tariff window on generic drugs, putting Sun Pharma, Aurobindo, Lupin and Zydus Life in focus, while Q1 results from Bandhan Bank and Indian Hotels came in ahead of last year and Infosys, BPCL, Bajaj Auto and IDFC First Bank headline today's earnings slate. GIFT Nifty is trading near 24,125, down about 60 points, pointing to a soft start.

Market mood — STRONG WALL STREET CUE MEETS ELEVATED CRUDE; PHARMA IN FOCUS ON US TARIFF RELIEF. Tuesday marked a second straight lower close, with the Sensex down 238 points and the Nifty below 24,200 on elevated crude and foreign selling, though breadth stayed balanced. The setup into Wednesday is mixed: Wall Street rallied overnight with all three indices breaking three-day losing streaks as chip stocks rebounded, while Brent held near USD 91 on US-Iran tensions. A US two-year zero-tariff window on generic drugs puts the pharma basket in focus, and Q1 prints from Bandhan Bank and Indian Hotels came in ahead of the prior year. GIFT Nifty near 24,125 points to a soft start.

Key stock news

• Sun Pharma and Generics - US Grants Two-Year Tariff Relief — The Indian generics exporters are the morning's clearest positive after the United States announced a two-year zero-tariff window on generic drugs, putting Sun Pharma, Aurobindo Pharma, Lupin and Zydus Life squarely in focus. All four carry material US-facing books, so the removal of tariff friction supports both volume and margin on the export line. Development
  US two-year zero tariff on generics | Sun Pharma, Aurobindo, Lupin, Zydus in focus | Volume and margin tailwind
• Infosys - Q1 Print with Guidance the Binary — Infosys headlines today's earnings slate, and the number that matters is the FY27 revenue guidance rather than the quarter itself. Street commentary points to a possible 50-basis-point trim to the top of the band, to 1.5%-3%, even as the operating margin is expected to improve toward 21.4% on cost efficiencies. We are constructive on large-cap IT after the improved demand tone from Tech Mahindra and the strong overnight move in US technology, but a guidance cut is the risk that could cap the sector's bounce. We would keep sizing measured into the print and let the guidance line, not the headline, set the trade. In focus
  Q1 FY27 today | FY27 guidance in focus (possible 50bps trim to 1.5-3%) | Margin seen ~21.4%
• Bandhan Bank - Profit Jumps as Provisions Fall — Bandhan Bank reported a strong June quarter, with net profit rising about 35% year-on-year to Rs. 501.7 crore and net interest income up 5.9% to Rs. 2,920.6 crore, while provisions and contingencies fell 40.5% and both gross and net NPAs improved sequentially. The print is a useful counterpoint to Monday's private-bank de-rating: a smaller lender can still deliver profit growth and asset-quality improvement together. Development
  Q1 FY27 | PAT Rs. 501.7 cr (+35% YoY) | NII Rs. 2,920.6 cr (+5.9%) | Provisions -40.5% | NPAs improved
• Indian Hotels - Margin Expansion Underlines Premium Demand — Indian Hotels delivered a clean quarter, with net profit up 20.8% year-on-year to Rs. 357.9 crore and revenue up 14.6% to Rs. 2,339.2 crore, while EBITDA rose to Rs. 753 crore and margins expanded 80 basis points to 31.1%. Margin expansion on top of double-digit revenue growth is exactly the profile we want from a premium-consumption name. We stay constructive on the hospitality and discretionary theme, where operating leverage and a firm room-rate cycle continue to support earnings, and see the Tata-backed franchise as a core holding within it. Development
  Q1 FY27 | PAT Rs. 357.9 cr (+20.8% YoY) | Revenue Rs. 2,339.2 cr (+14.6%) | EBITDA margin 31.1% (+80bps)
• Maruti Suzuki - Price Hike to Offset Input Costs — Maruti Suzuki has decided to raise prices across its portfolio by up to Rs. 30,000, effective August 2026, to offset a continued rise in input costs. A broad-based hike protects margin but tests demand elasticity at the entry level, where the volume recovery has been the most fragile. We stay neutral-to-selective on the passenger-vehicle makers: the pricing action supports the earnings line, but we would want confirmation that volumes hold through the festive build before turning more constructive on the name. In focus
  Portfolio price hike up to Rs. 30,000 | Effective August 2026 | Input-cost pass-through | Demand elasticity the watch
• BPCL and Oil-Marketing Basket - Reporting into a Rising-Cost Quarter — BPCL headlines the energy slate today, reporting into a quarter in which Brent has pushed back toward USD 91 on US-Iran tensions. For the oil-marketing companies, a rising crude price compresses marketing margins unless retail fuel prices are allowed to follow, which keeps BPCL, HPCL and IOC on the back foot. We stay cautious on the marketing basket while the Hormuz premium is live and prefer the upstream producers - ONGC and Oil India - as the clean expression of the crude move. We would treat the BPCL print as a read on how much of the crude rise the marketing margin absorbed. In focus
  BPCL Q1 today | Brent near USD 91 pressures marketing margins | Upstream preferred over OMCs

Earnings watch

Global factors

A. US Grants Two-Year Zero Tariff on Generics

• The United States has opened a two-year zero-tariff window on generic drugs, removing a key cost friction for the Indian exporters that supply a large share of the US generics market.
• Sun Pharma, Aurobindo Pharma, Lupin and Zydus Life carry the most material US-facing books and are the names in focus at the open.
• The measure supports both export volume and margin, and lands at a time when the broader tariff calendar has otherwise been a source of uncertainty.
• Pharma has been a relative haven through the recent crude-driven volatility, and the tariff window adds a fresh, specific catalyst to the sector.

B. Crude Near USD 91 Meets a Wall Street Rebound

• Brent held near USD 91 a barrel, up about 2.1%, on US-Iran tensions after a further round of strikes, keeping supply risk in the price.
• Overnight, US equities rallied: the Dow rose 0.74% to 52,224.64, the S&P 500 added 0.89% to 7,509.20 and the Nasdaq gained 1.29% to 25,837.21, all breaking three-day losing streaks.
• Semiconductor stocks led the rebound on strong Taiwan and South Korea export data, improving the global-technology tone into the Indian IT prints.
• The rupee sat near Rs. 96.36 to the dollar, within a weekly range of about 96.04 to 96.58, with the crude premium the dominant influence on the currency.

C. Q1 Earnings Season Broadens

• Around 250 companies are reporting June-quarter results across the 20-25 July window, with Infosys, Paytm, Bajaj Auto, BPCL, NTPC and IDFC First Bank among today's names.
• Bandhan Bank set an encouraging tone with net profit up about 35% and provisions down 40.5%, while Indian Hotels expanded EBITDA margin 80 basis points to 31.1%.
• Maruti Suzuki announced a portfolio-wide price increase of up to Rs. 30,000 from August to offset input costs, a signal on both cost pressure and pricing power.
• Market breadth stayed balanced on Tuesday, with 2,087 shares advancing against 1,942 declining, suggesting the index-level weakness was concentrated rather than broad.

Today’s watchlist

• Pharma Tariff Relief — The US two-year zero-tariff window on generics is a clean, specific catalyst for the US-facing exporters - Sun Pharma, Aurobindo, Lupin and Zydus Life.
• Infosys FY27 Guidance — The guidance line is the binary for IT today, not the quarter itself - a 50-basis-point trim to the top of the revenue band is the risk against a margin seen near 21.4%. We stay constructive on large-cap IT but keep sizing measured and let the guidance set the trade
• Brent Above USD 90 — Crude near USD 91 on US-Iran tensions keeps the rupee soft, the import bill rising and the OMC basket squeezed, while supporting upstream ONGC and Oil India - the position we hold on both sides of that trade until crude cools
• BPCL and OMC Margins — BPCL reports today into a rising-crude quarter, and the marketing-margin line reads across the whole OMC basket. We stay cautious on BPCL, HPCL and IOC while the Hormuz premium is live and prefer upstream as the clean crude expression
• USD / INR Near Record Low — The rupee sits near Rs. 96.36 within a 96.04-96.58 weekly range, driven by the crude premium. A sustained break past 96.58 would keep the import bill and imported-inflation risk in focus and cap conviction on rate-sensitive sectors
• Nifty 24,000-23,800 Support — With the index below 24,200 and GIFT Nifty near 24,125 pointing to a soft start, the 24,000-23,800 band matters more than the 24,300-24,600 resistance today. We would let the pharma trade lead and keep the rest of the book light into the level

Sectoral observations

Geopolitical tracker

Closing summary

Wednesday opens on a two-sided setup. The domestic catalyst is pharma: the United States has granted a two-year zero-tariff window on generic drugs, putting Sun Pharma, Aurobindo, Lupin and Zydus Life in focus and adding a specific, sizeable positive to a sector that has been a relative haven through the crude-driven volatility. The global cue is supportive too, with Wall Street rallying overnight - the Dow up 0.74%, the S&P 500 up 0.89% and the Nasdaq up 1.29%, all breaking three-day losing streaks as chip stocks rebounded. Working the other way, Brent held near USD 91 on US-Iran tensions, keeping the rupee near Rs. 96.36 and the oil-marketing basket pressured. Q1 results stay heavy, with Bandhan Bank and Indian Hotels reporting strong numbers and Infosys, BPCL, Bajaj Auto and IDFC First Bank on today's slate. GIFT Nifty near 24,125 points to a soft start.

Cautious: the OMC basket (BPCL, HPCL, IOC), aviation and paints while the crude premium is live, and neutral-to-selective on Maruti until entry-level volumes confirm the price hike sticks. Watchlist: the Infosys FY27 guidance line as the binary for IT, BPCL's marketing margin as the read on OMC crude absorption, and USD/INR past 96.58 as the crude pressure gauge. Respect 24,300-24,600 as resistance and 24,000-23,800 as the support that matters, and let the pharma trade lead while keeping the rest of the book light into a session where the macro headline can move faster than the earnings.

Issued for knowledge and general awareness only. Not investment advice, research, or a recommendation to buy or sell any security. PCJ Holdings Pvt. Ltd. does not provide research or investment-advisory services. Investments in the securities market are subject to market risks; read all related documents carefully before investing.